The IDO1 inhibitor combos were one of the main immunotherapy competitors to the Cavatak/Keytruda combo in multiple cancer indications. The combo just failed a phase III trial in advanced melanoma.
Looks to me that Cavatak is now worth much more than $1.75/share ....
Www.endpts.com/keytruda-epacadostat-combo-crashes-in-phiii-melanoma-study-raising-questions-about-the-future-of-ido-for-incyte/
Add to My Watchlist
What is My Watchlist?